Literature DB >> 26271726

Fulminant Central Plus Peripheral Nervous System Demyelination without Antibodies to Neurofascin.

Atay Vural1, Rahşan Göçmen2, Aslı Tuncer Kurne1, Kader Karlı Oğuz2, Çağrı Mesut Temuçin1, Ersin Tan1, Rana Karabudak1, Edgar Meinl3, Sevim Erdem Özdamar1.   

Abstract

BACKGROUND: Combined central and peripheral nervous system demyelination is a rare and poorly described phenomenon. Recently, anti-neurofascin antibodies were reported to be positive in 86% of these patients in a Japanese cohort. Yet, there seems to be a clinical, radiological, and serological heterogeneity among these patients. In this report, our aim is to describe characteristics of our patients with this entity and compare with others in the literature.
METHODS: We report clinical, electrophysiological, radiological, and laboratory characteristics of five patients with both multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy from our institutional database containing 1890 MS patients.
RESULTS: Three patients presented with extensive, active demyelination of both central nervous system and peripheral nervous system with hypertrophic peripheral nerves. Plexuses, trunks, division and cords were involved in the process. Oligoclonal band was negative. Conduction block was not detected. Corticosteroid treatment was not adequate. Others had a slowly progressive clinical course. Serum anti-neurofascin antibody was negative. Review of the literature revealed similar cases with active disease, early-onset hypertrophic peripheral nerves, and central demyelination, in addition to other cases with an insidious course.
CONCLUSIONS: Patients with combined central and peripheral demyelination form a spectrum. Some patients may have an antibody-mediated syndrome with or without anti-neurofascin antibodies and others seem to represent a coincidence.

Entities:  

Keywords:  Multiple sclerosis; anti-neurofascin antibody; chronic inflammatory demyelinating polyradiculopathy; magnetic resonance imaging

Mesh:

Substances:

Year:  2015        PMID: 26271726     DOI: 10.1017/cjn.2015.238

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  3 in total

1.  Combined central and peripheral demyelination after COVID-19 vaccination.

Authors:  Pedro Coelho; André Paula; Isabel Vidal Martins; Catarina Falcão de Campos; João Ferreira; Ana Patrícia Antunes; Luísa Albuquerque
Journal:  J Neurol       Date:  2022-05-18       Impact factor: 6.682

2.  Neurofascin (NF)155- and NF186-Specific T Cell Response in a Patient Developing a Central Pontocerebellar Demyelination after 10 Years of CIDP.

Authors:  Juliane Klehmet; Max Staudt; Jan-Markus Diederich; Eberhard Siebert; Edgar Meinl; Lutz Harms; Andreas Meisel
Journal:  Front Neurol       Date:  2017-12-22       Impact factor: 4.003

Review 3.  Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance.

Authors:  Atay Vural; Kathrin Doppler; Edgar Meinl
Journal:  Front Immunol       Date:  2018-05-14       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.